Blood test may reveal if radiotherapy is working for liver cancer

NCT ID NCT06885879

Recruiting now Knowledge-focused Sponsor: Chinese University of Hong Kong Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study looks at how pieces of tumor DNA circulating in the blood change in 15 liver cancer patients receiving a precise type of radiotherapy called SBRT. Researchers will take blood samples before, during, and up to 6 months after treatment to see if these DNA changes can help tell if the cancer is responding. The goal is to find a better way to monitor treatment than relying on standard scans, which can be misleading for months after radiotherapy.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Stereotactic Body Radiation Therapy (SBRT)
What this could lead to: If successful, this could lead to a simple blood test to monitor how well radiotherapy is working for liver cancer patients, replacing unclear imaging results.
What could go wrong: This is a very small, early study with only 15 participants. It is designed to observe changes, not to prove a treatment works, so results may not apply broadly.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HCC - HEPATOCELLULAR CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hepatocellular carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HCC - HEPATOCELLULAR CARCINOMA

Contacts and locations

Locations

Department of Clinical Oncology, Prince of Wales Hospital
RECRUITING

Hong Kong, Hong Kong

More trials for these conditions

Other studies related to the condition(s) this trial covers.